Innovation and Investment Propel DNA Encoded Library Market: AI Integration and Strategic Alliances Fuel Remarkable Growth

News provided by

Oct 18, 2023, 10:15 ET

DUBLIN, Oct. 18, 2023 /PRNewswire/ -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The global DNA encoded library market is poised for substantial growth, with an estimated worth of USD 840 million in 2023 and a projected compound annual growth rate (CAGR) of 16% during the forecast period spanning 2023 to 2035.

DNA Encoded Libraries: A Catalyst for Drug Discovery

DNA encoded libraries (DELs) have emerged as a transformative platform for drug discovery, revolutionizing the synthesis and screening of millions of small molecules within a single study. DELs consist of small molecules tagged with DNA, serving as unique barcodes for molecule identification. Their adoption has gained momentum in recent years, significantly expediting drug discovery by reducing time and cost compared to traditional high-throughput screening methods.

Rising Demand for Innovative Therapies Drives Market Growth

The demand for innovative therapies to combat complex diseases such as oncological and neurological disorders has propelled the development of DNA encoded libraries. Pharmaceutical and biotechnology companies, academic institutions, and contract research organizations have increasingly embraced DEL technology, further driving market growth. With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.

Key Market Insights:

Lead Screening and Optimization: DELs, with their sophisticated combinatorial drug discovery capabilities, have enabled the synthesis and screening of vast collections of small molecule compounds. They facilitate the identification of pharmacological leads, including macrocycles, natural products, and small molecules, with some libraries containing up to 40 trillion unique molecules. DELs are instrumental in lead optimization against challenging targets, accelerating drug development.
Competitive Landscape: The market features around 50 companies, both large and small, providing various services related to DNA encoded libraries for drug discovery, including hit identification, optimization, and lead generation. Notably, several major pharmaceutical companies, such as Amgen, GSK, Pfizer, Roche, Novartis, AstraZeneca, Bristol Myers Squibb, Sanofi, and Janssen, have adopted DEL technology for drug discovery.
AI and Machine Learning Integration: The integration of artificial intelligence (AI) and machine learning has found a natural fit in DNA encoded chemical library platforms, enhancing data analytics capabilities. Companies like Insitro and Google Research have embraced this technology to expedite drug discovery.
Strategic Alliances and Acquisitions: Stakeholders have formed strategic partnerships and made acquisitions to expand their capabilities. Over 175 partnerships have been inked in the DNA encoded library market since 2010. For example, X-Chem acquired Glamorous.AI to incorporate AI in DELs.
Funding and Intellectual Property: The market has attracted significant investment, with close to USD 2.5 billion raised in recent years. Venture capital firms have been active supporters. Additionally, patent filings in the industry have grown at a rate of over 20% in the last decade, reflecting rising interest in DEL technology.

Market Analysis and Regional Dominance:

The global DNA encoded library market is estimated to reach USD 840 million in 2023. North America is expected to hold the largest market share, with more than 70% of the market captured by players based in North America and Europe by 2035. These companies will support pharmaceutical drug developers in their drug discovery initiatives through various business models.

Leading DNA Encoded Library Companies:

Key players in the DNA encoded library market include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec, and X-Chem.

Recent Developments:

Recent initiatives in the DNA encoded library market include collaborations between Philogen and Google, X-Chem and Kymera Therapeutics, and X-Chem and Sironax, focusing on the utilization of machine learning, DEL-based screening services, and drug discovery pipeline support.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. BUSINESS MODEL ANALYSIS

6. COMPANY COMPETITIVENESS ANALYSIS

7. COMPANY PROFILES

8. PARTNERSHIPS AND COLLABORATIONS

9. FUNDING AND INVESTMENT ANALYSIS

10. PATENT ANALYSIS

11. BIG PHARMA INITIATIVES

12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

14. CONCLUDING REMARKS

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

1859, Inc.
6 Dimensions Capital
AbbVie
Abilita Bio
Actelion Pharmaceuticals
Aduro Biotech
Agent Capital
Air Street Capital
Alex's Lemonade Stand Foundation
Alexandria Venture Investments
Alexion
Aligos Therapeutics
ALK
Alkermes
Almac Discovery
Almirall
AlphaMa
Altitude Life Science Ventures
Amadeus Capital Partners
Amgen
Anagenex
Anavo Therapeutics
Andreessen Horowitz
Animol Discovery
Anterra Capital
Arbutus Biopharma
ARCH Venture Partners
Arclight
Arvinas
ASINEX
Astellas Pharma
Astellas Venture Management
AstraZeneca
Asymmetry Capital Management
Atlas Venture
AviSyn Pharma (acquired by X-Chem)
Azenta Life Sciences
Bain Capital Life Sciences
BASF
Bayer
Baylor College of Medicine
BGF
BigRio
Bill & Melinda Gates Foundation
BioAge Labs
BioDuro-Sundia
Biogen
BIONET
BOC Sciences
Boehringer Ingelheim
Borealis Ventures
Boxer Capital
Bpifrance
Bridge Biotherapeutics
Bristol Myers Squibb
BVF Partners
C4X Discovery
Cambridge Enterprise
Cambridge Molecular
Canada Pension Plan Investment Board
Cancer Research Technology
Cancer Research UK
Carterra
Casdin Capital
Casma Therapeutics
Catalio Capital Management
CDH Investments
Cedilla Therapeutics
Central European Institute of Technology
Charles River
Charles River Ventures
ChemDiv
ChemRoutes
Chemspace
Citadel Discovery
Cocrystal Pharma
Columbia University
ComInnex (acquired by X-Chem)
Confo Therapeutics
Crelux
Cyclofluidic
D. E. Shaw
Daewoong Pharmaceutical
Daiichi Sankyo
DCVC Bio
Deep Track Capital
Deluge Biotechnologies
DICE Therapeutics
Domainex
Dorian Therapeutics
Dresden University of Technology (TUD)
Driehaus Capital Management
Duke University
DyNAbind
EcoR1 Capital
Edelris
Eli Lilly
Enamine
Encodia
Endevica Bio
Enko
EQRx
ETH Zurich
European Regional Development Fund (ERDF)
Eventide Asset Management
Evotec
Exo Therapeutics
Finistere Ventures
Fisher Scientific
Foresite Capital
Forma Therapeutics
Franzini Research
Galapagos
Genentech
GenScript
GHO Capital
Gilead Sciences
Glamorous AI (acquired by X-Chem)
GlaxoSmithKline (GSK)
Global Blood Therapeutics
Google
Google Ventures
Harvard College
Haystack Sciences (acquired by insitro)
Heptares Therapeutics
High-Tech Grunderfonds (HTGF)
HitGen
Hope City Church
HotSpot Therapeutics
Howard Hughes Medical Institute
Innovate UK
Inscripta
insitro
IntelliSyn (acquired by X-Chem)
InterX (acquired by NeoTX)
Janssen
Janus Henderson Investors
Johnson & Johnson
Kaken Pharmaceutical
Khosla Ventures
Kymera Therapeutics
Leadyond Capital
LEO Pharma
LG Chem
LGC Biosearch Technologies
Life Chemicals
Lipigon
Liverpool ChiroChem
Logos Capital
LoQus23 Therapeutics
Lux Capital
M Ventures
Macroceutics (acquired by HotSpot Therapeutics)
Maruho
Max Planck Institute of Molecular Physiology (MPI)
Mcule
MD Anderson Cancer Center
MedChemExpress (MCE)
Menlo Ventures
Merck
Mitsubishi Tanabe Pharma
MolPort
Morningside Ventures
Morphic Therapeutic
Namiki Shoji
Navitor Pharmaceuticals
Neotribe Ventures
NetVation DL Medicine
New Leaf Venture Partners
Newpath Partners
Nextech Invest
Nitrase Therapeutics
Northpond Ventures
Northwestern University
Novalis LifeSciences
NovAliX
Novartis
Novartis Venture Fund
Nuevolution (acquired by Amgen)
Nurix Therapeutics
O2h Ventures
Obvious Ventures
OMass Therapeutics
Oncodesign
Ono Pharmaceutical
Orbit Discovery
Orexia
Osage University Partners
Otsuka Pharmaceutical
Oxford Sciences Innovation
Oxford University
PACS1 Syndrome Research Foundation
Pappas Capital
Parkwalk Advisors
Perceptive Advisors
Perivoli Innovations
Pfizer
PharmaBlock Sciences
Pharmacelera
Pharmaceutical Product Development (PPD)
Pharmaron
PharmStars
Philochem
Philogen
PhoreMost
PhyNexus (acquired by Biotage)
Pioneering Medicines
Pivotal bioVenture Partners
Plexium
Praecis Pharmaceuticals (acquired by GSK )
Princeton University
Proteros Biostructures
PROvendis
PsyBrain
Pulsar Bio
RA Capital Management
Receptor.AI
Recludix Pharma
Redmile Group
Relay Therapeutics
Roche
Roivant Sciences
RT Ventures
S.R. One
Sahsen Ventures
Salipro Biotech
Samsara BioCapital
Sands Capital
SanegeneBio
Sanofi
Sanofi Ventures
SciLifeLab
Scilligence
Serengen
Servier
Signel IX
Simcere Pharmaceutical
Sironax
Sofinnova Partners
SoftBank Vision Fund
Soleus Capital
SpiroChem
Sun Pharma Advanced Research Company (SPARC)
Surveyor Capital (a Citadel company)
Symeres
SyntheX
Taiho Pharmaceutical
Takeda
Tasly Pharmaceuticals
Tavistock Group
TCG Crossover (TCG X)
Technical University of Dortmund
Technology Founder Fund Saxony (TGFS )
Temasek
The California Institute for Biomedical Research (Calibr)
The Column Group (TCG)
The Scripps Research Institute
Theseus Pharmaceuticals
Third Rock Ventures
Trend Investment Group
Trilo Therapeutics
TUDAG
Two Sigma Ventures
UNC Drug Discovery Initiative
University of Edinburgh
University of Manchester
University of Pennsylvania
UPPthera
Valo Health
Veritas In Silico
Vernalis Research (acquired by HitGen)
Vertex Pharmaceuticals
Vipergen
Viva Biotech
Wake Forest University
Warp Drive Bio
Wellington Management Company
WuXi AppTec
X-Chem
XtalPi
Zai Lab
ZebiAI (acquired by Relay Therapeutics)

For more information about this report visit https://www.researchandmarkets.com/r/eswhnf

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets